Piper Sandler Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $200
Piper Sandler Sticks to Their Buy Rating for Natera (NTRA)
Trade Alert: Independent Director Of Natera Gail Marcus Has Sold Stock
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages
Guardant Health Shares Are Trading Higher After a Jury Issued a Decision in the Company's Favor Regarding a False Advertising Case Filed by Natera Concerning Statements Made About Guardant's Reveal Test.